Stock AAQ1 AAP IMPLANTATE AG
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases aap Implantate AG

Equities

AAQ1

DE000A3H2101

Market Closed - Xetra
Other stock markets
 11:36:16 2024-05-16 am EDT 		After market 11:57:42 am
1.34 EUR -1.47% Intraday chart for aap Implantate AG 1.405 +4.85%
2021 Aap Implantate AG Announces Sales Results for the Second Quarter and Half Year Ended 30 June 2021 CI
2021 Aap Implantate Ag Reports Earnings Results for the Full Year Ended December 31, 2020 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aap Implantate AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
Aap closes Q1 2024 with sales growth of 5.6% and positive developments at all operating levels and makes a strong start to Q2 2024
EQ
NVR: aap Implantate AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
Aap successfully places a 10% capital increase from authorized capital at EUR 1.10 with exclusion of subscription rights
EQ
Aap Implantate AG: aap postpones publication of the consolidated financial statements 2023 due to staff shortages
EQ
Aap 100% approval of the proposed resolution to amend the terms and conditions of the mandatory convertible bond 2023/2028
EQ
Aap Implantate AG: Capital increase from authorized capital with exclusion of subscription rights
EQ
Aap proposes to the bondholders of the mandatory convertible bond 2023/2028 an amendment to the bond terms and conditions to enable the bondholders to exercise their conversion rights earlier
EQ
After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year
EQ
Aap Implantate : with positive EBITDA in Q2 and H1/2021 for first time since focusing on trauma and significant sales growth of +74% (Q2) and +37% (H1)
PU
Aap Implantate : with positive EBITDA in Q2 and H1/2021 for first time since focusing on trauma and significant sales growth of +74% (Q2) and +37% (H1)
EQ
Q1/21: Successful start to the year with sales growth (+9%) and significant earnings improvement (+91%) despite still burdening COVID-19 pandemic - restructuring successes clearly visible
EQ
2020 financial statements: visible results under restructuring with significantly improved Recurring EBITDA (+28%) in challenging times of COVID-19 pandemic
EQ
Q1/2021: Solid start to year with 9% sales growth despite still burdening COVID 19 pandemic; more than 500 surgeries in US mark new high; Q2 order book well filled
EQ
Aap Implantate : Publication of annual financial statements 2020 on 30 April 2021
EQ
FY/2020: Sales of EUR 9.3 million in Corona year in upper half of guidance - dynamic sales growth in USA (+41%); significant sales growth and positive EBITDA in trauma business planned for FY/2021
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AAQ1 Stock
  4. News aap Implantate AG
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW